查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835273

医院感染治疗市场（按药物类别、给药途径、最终用户、分销管道和应用）—2025-2032 年全球预测

Hospital Infection Therapeutics Market by Drug Class, Route Of Administration, End User, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医院感染治疗市场规模将达到 122.8 亿美元，复合年增长率为 8.52%。

主要市场统计数据
基准年2024年 63.8亿美元
预计2025年 69.2亿美元
预测年份：2032年 122.8亿美元
复合年增长率（%） 8.52%

简要介绍医院感染治疗的临床、商业和营运背景，强调采取综合策略应对措施的必要性

医院获得性抗菌药物仍然是病患安全和医疗品质的核心支柱，它与临床实践、供应链韧性和监管监督息息相关。近年来，采购、抗菌药物管理和分销管道方面存在的漏洞暴露无遗，亟需采取更全面的观点，将临床重点与商业性现实结合。本执行摘要概述了医院领导、製造商和经销商在製定策略和营运应对措施时必须考虑的关键主题。

这种模式的特点是各种因素的融合，包括病原体谱和抗药性模式的演变、新型抗病毒药物和抗真菌药物的成熟、消毒通讯协定的持续重要性，以及采购团队为确保关键疗法的持续可及性而承受的日益增加的压力。因此，相关人员必须在紧急营运需求与在产品线开发、管理计画和替代筹资策略的中长期投资之间取得平衡。本引言为系统性地探讨转型转变、关税相关阻力、细分资讯、区域差异、竞争动态、建议行动以及本报告所依据的研究严谨性奠定了基础。

分析重新定义医院感染药物和相关人员合作的临床、製造和分销转型

医院感染治疗领域正经历变革时期期，其驱动力来自几个趋势，这些趋势正在重塑临床决策和供应链结构。快速诊断和就地检验的进步使得治疗方法选择更具针对性，并逐渐将重点从广泛的经验性方案转向精准标靶治疗。同时，管理计画与采购奖励的连结日益紧密，形成了一个反馈循环，处方决策将同时考虑临床疗效和抗药性缓解的必要性。

分销模式与临床创新同步发展。采购日益数位化、线上药局履约的扩张以及批发商利润的压力，迫使医院和医疗系统重新评估直接采购、代销模式和策略库存缓衝。肠外给药和无菌注射剂向专业化生产的转变，加上对品质和法规合规性的严格审查，意味着供应的连续性取决于强大的供应商合格和关键投入的地理分布。总而言之，这些转变要求临床领导者与供应链和商业团队更紧密地合作，以使治疗策略与采购可靠性和成本控制相一致。

全面分析新的关税动态如何加剧供应链脆弱性、采购复杂性以及医院治疗的临床替代策略

即使关税政策的改变不会直接影响成品药品，也会对医院感染治疗产品整体产生巨大影响。对原料药、无菌製剂、一次性设备和包装征收更高的关税，可能会增加到岸成本，并挤压製造商和经销商的净利率。因此，采购团队在成本预测和合约谈判方面面临更大的复杂性，製造商正在重新评估其供应商布局，并考虑将关键生产环节回流或近岸外包。

关税环境也加剧了现有肠外和无菌产品供应链的脆弱性，专用设备和检验的生产基地限制了产能的快速扩张。依赖即时库存模式的医院将更容易受到间歇性供不应求的影响，迫使其进行策略性调整，例如安全库存、多方采购以及更长的合约期限，其中包含处理不可抗力和成本转嫁的条款结构。同时，进口成本的上升将鼓励对本地製造业的投资，但由于此类转型需要资金、监管调整和时间，因此短期影响将主要透过合约策略和库存政策来管理。

临床上，与关税相关的变化可能会改变某些药物类别的供应和采购优先顺序。机构可能会优先考虑治疗等效的学名药或替代抗菌剂型，以维持医疗服务的连续性。因此，抗菌药物管理团队必须与采购和处方委员会合作，更新治疗途径，并确保替代药物在满足管理目标的同时保持临床有效性。整体而言，关税变化是一种强制机制，有助于促进临床、供应链、监管和财务职能之间的协调。

按药物类别、给药途径、最终用户、分销管道和应用分類的关键细分洞察

要了解市场，需要详细了解药品类别、给药途径、最终用户、分销管道和应用。药物类别包括抗生素、抗真菌药物、消毒剂和抗病毒药物；抗生素包括卡巴培南类、头孢菌素类、Fluoroquinolones和青霉素类等亚类；抗真菌药物包括Azole、棘白菌素类和Polyenes；消毒剂包括酒精製剂、洛赫西定和碘；每个类别都有不同的临床使用模式、管理考虑、製造要求和监管途径，这些因素共同影响采购重点和医院处方笺。

给药途径——吸入、口服、肠外和局部——决定了临床路径和物流，使其成为决定临床部署和供应复杂性的关键因素。肠外给药特别分为肌肉注射、静脉注射和皮下注射，给药需要专门的无菌生产、低温运输考量和护理技能。最终用户，包括门诊手术中心、诊所、居家医疗机构和医院，具有不同的购买力、储存基础设施和治疗通讯协定，需要量身定制的分销方式和患者教育策略。分销管道也各不相同，包括医院药房、线上药房、零售药房和批发商，每个管道都有不同的前置作业时间、合约规范和合规义务。

治疗方法选择和库存规划由应用细分驱动：安宁疗护、预防治疗和治疗。而治疗又分为经验性疗法和标靶治疗，每种疗法都需要不同的诊断和管理支持。整合这些细分层面，使相关人员能够更好地协调临床路径与供应链设计，将合适的配方、途径和分销管道与合适的最终用户和应用相匹配。

关键区域洞察和地理动态将如何影响临床应用、製造和分销策略

美洲、欧洲、中东和非洲以及亚太地区的区域动态对治疗药物的可近性、监管预期和商业策略有重大影响。在美洲，医院系统的整合和对基于价值的采购的重视推动了对具有明显临床和经济效益的治疗药物的需求，分销网络通常以集中式集团采购和整合供应协议为导向。相较之下，欧洲、中东和非洲的法规环境和采购框架各不相同，国家法规、报销机制和区域製造地决定药物的可及性和定价。强调抗生素管理和感染预防的政策倡议也因司法管辖区而异。

亚太地区呈现出多元化的动态，一些市场医疗产能快速扩张，而其他市场则拥有先进的製造能力。该地区一些国家优先发展本地生产和出口导向製药产业，影响原料药和无菌成分的全球供应链。这些地理差异要求製造商和经销商采取差异化的市场开发方法，投资监管情报，并制定针对特定区域的供应链冗余。总体而言，区域策略必须考虑监管时间表、采购实践、製造集中度以及临床实践的差异，以确保药品的可用性和适当的临床使用。

公司对竞争定位、创新重点和供应链作用的关键见解

竞争格局多种多样，涵盖跨国製药创新企业、专注于新型抗生素和抗病毒药物的专业生物技术公司、学名药製造商以及促进医院可及性的经销商。拥有广泛感染疾病产品组合的行业领导者通常将抗病毒和抗生素研发与大规模生产和成熟的分销网络相结合，从而能够快速部署经临床检验的新型疗法。专业生物技术公司和学术衍生公司通常是下一代药物和辅助性治疗的来源，而学名药和契约製造製造商在维持成本效益和生产弹性方面发挥关键作用。

分销和药房服务供应商正日益透过附加价值服务（例如临床支援工具、管理分析和库存管理解决方案）来凸显自身差异化。这一趋势凸显了製造商与经销商伙伴关係的重要性，以确保及时的供应和临床医生教育能够支持管理目标和处方决策。此外，投资于无菌生产能力和品质系统的公司在医院肠外用药市场中占据有利地位，该市场由于监管审查和对生产检验的要求而面临较高的进入门槛。深入了解此类企业策略可以帮助相关人员评估合作伙伴的选择、潜在的收购和合作机会，从而增强供应的连续性和临床疗效。

为行业领导者提供切实可行的建议，以增强韧性、管理和商业性绩效

产业领导者应优先考虑跨职能管治，将临床、采购、监管和商业团队整合在一起，共同製定配方决策、合约结构和应急计画。加强供应商资格认证流程，并实现原料药和无菌成分供应商的多元化，可以减少地理和政策干扰带来的风险。同时，投资诊断验证和管理分析，可以将药物利用转向标靶治疗，保持临床有效性，并减缓抗药性趋势。

商业和分销策略必须适应不断变化的采购行为，提供灵活的合约模式、经过认证的供应保证以及临床应用的教育支援。拥有无菌生产能力和强大品质系统的製造商应考虑产能讯号和策略伙伴关係，以满足医院的需求。此外，将情境规划纳入策略评估，可以帮助组织应对关税变化、监管变化和突发需求激增，明确定义库存调整、替代采购或治疗方案替换的触发点。结合这些步骤可以增强应对能力，同时使商业性奖励与临床品质目标保持一致。

调查方法和资料来源、分析框架以及研究结果背后的检验方法的描述

调查方法结合了临床领导者、采购专业人员和行业高管的初步意见，以及对监管备案文件、品质指南和开放原始码行业报告的二次分析。定性访谈揭示了营运限制和应用障碍的相关背景，而供应链图谱则确定了原料药采购、无菌成分和分销流程中的关键节点。此分析框架将临床路径图谱与供应商风险评估和商业管道评估相结合，以产生全面的洞察。

检验结合了访谈回馈、製造商资讯揭露以及公开的监管行动摘要。采用情境分析来评估在供应中断和政策变化下的韧性，尤其关注肠外製剂的生产限制和分销管道摘要。强调假设的透明度和方法步骤的可重复性，以便相关人员能够根据其内部决策调整方法，并根据需要进行有针对性的尽职实质审查。

结论：临床结果、供应连续性和协作实施的策略重点总结

医院感染治疗兼具临床紧迫性与运作复杂性。确保患者安全和有效获得治疗，需要临床管理、采购政策、生产策略和分销设计等方面的全面行动。近期贸易政策变化、临床诊断技术的不断发展以及分销模式的转变，都增加了跨职能协调和应急计划的需求。积极实现供应多元化、投资诊断主导製剂并建立灵活商业协议的组织将能够保持连续性并支持最佳临床疗效。

最终，成功取决于将洞见转化为实践，例如根据管理目标制定方案，确保关键无菌产品的多种供应来源，以及利用能够提供临床推广和库存解决方案的伙伴关係。采取策略性和全面性的方法将有助于医院、製造商和经销商缓解短期中断，并建立应对未来感染护理挑战所需的适应能力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 医院抗菌药物管理计画的成长，优化了抗生素的使用，减少了抗药性的出现
  • 引进快速分子诊断技术，可在患者入院后数小时内进行针对性感染治疗
  • 加强人工智慧驱动的预测分析的整合，以便及早发现医院内感染
  • 针对加护病房中耐多药铜绿假单胞菌的噬菌体混合物的开发
  • 预防困难梭状桿菌感染疾病復发的辅助单株抗体辅助性治疗的出现
  • 在医疗设备中引入抗菌表面涂层，以防止导管中生物膜的形成
  • 扩大以远端医疗为基础的感染疾病咨询服务，以管理住院患者的抗菌通讯协定
  • 管理方案要求即时追踪和报告整个医院网路的抗生素使用情况
  • CRISPR-Cas 抗菌药物取得进展，旨在选择性消除医院中的抗药性菌株
  • 利用次世代定序即时监测抗性基因通路

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 医院感染治疗市场（依药物类别）

  • 抗生素
    • 卡巴培南类
    • 头孢菌素类
    • Fluoroquinolones
    • 大环内酯类
    • 青霉素
  • 抗真菌药物
    • Azole
    • Echinocandins
    • Polyenes
  • 消毒剂
    • 酒精类
    • 洛赫西定
    • 带碘化合物
  • 抗病毒药物
    • 抗B肝病毒
    • 抗HCV
    • 抗爱滋病毒
    • 抗流感

9. 医院感染治疗药物市场（依给药途径）

  • 吸入
  • 口服
  • 肠外
    • 肌肉注射
    • 静脉
    • 皮下
  • 外用

第 10 章医院感染治疗药物市场（依最终使用者）

  • 门诊手术中心
  • 诊所
  • 家庭环境
  • 医院

第十一章 医院感染治疗药物市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局
  • 批发商

第十二章医院感染治疗药物市场（依应用）

  • 安宁疗护
  • 预防
    • 术后
    • 术前
  • 治疗
    • 经验
    • 标靶治疗

第十三章医院感染治疗药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章医院感染治疗药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章医院感染治疗药物市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • DAIICHI SANKYO COMPANY
Product Code: MRR-43127F7278A5

The Hospital Infection Therapeutics Market is projected to grow by USD 12.28 billion at a CAGR of 8.52% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.38 billion
Estimated Year [2025] USD 6.92 billion
Forecast Year [2032] USD 12.28 billion
CAGR (%) 8.52%

Concise introduction framing the clinical, commercial, and operational context for hospital infection therapeutics while highlighting the need for integrated strategic responses

Hospital infection therapeutics remain a central pillar of patient safety and quality of care, intersecting clinical practice, supply chain resilience, and regulatory oversight. Recent years have exposed vulnerabilities across procurement, antimicrobial stewardship, and distribution channels, requiring a more integrated perspective that aligns clinical priorities with commercial realities. This executive summary synthesizes critical themes that hospital leaders, manufacturers, and distributors must consider when shaping strategy and operational responses.

The landscape is characterized by a convergence of factors: evolving pathogen profiles and resistance patterns; the maturation of novel antiviral and antifungal agents; the sustained importance of antiseptic protocols; and mounting pressure on procurement teams to ensure uninterrupted access to key therapies. Consequently, stakeholders must balance acute operational needs with medium- to long-term investments in pipeline development, stewardship programs, and alternative sourcing strategies. This introduction sets the stage for a structured examination of transformative shifts, tariff-related headwinds, segmentation intelligence, regional differences, competitive dynamics, recommended actions, and research rigor that underpins the report.

Analysis of the converging clinical, manufacturing, and distribution transformations that are redefining hospital infection therapeutics and stakeholder collaboration

The hospital infection therapeutics sector is undergoing transformative shifts driven by several concurrent trends that are reshaping clinical decision-making and supply chain structures. Advances in rapid diagnostics and point-of-care testing are enabling more targeted therapy selection, which is prompting a gradual pivot from broad empirical regimens to precision-targeted approaches. At the same time, stewardship programs are increasingly intertwined with procurement incentives, creating a feedback loop in which formulary decisions are informed by both clinical efficacy and resistance mitigation imperatives.

Parallel to clinical innovation, distribution models are evolving. Increased digitalization of procurement, growth in online pharmacy fulfillment, and pressure on wholesaler margins are motivating hospitals and health systems to reassess direct purchasing, consignment models, and strategic inventory buffers. Manufacturing trends are also significant; a shift toward specialized manufacturing for parenteral formulations and sterile injectables, combined with increasing scrutiny of quality and regulatory compliance, means supply continuity depends on robust supplier qualification and geographic diversification of critical inputs. These shifts collectively demand that clinical leaders work more closely with supply chain and commercial teams to harmonize therapeutic strategy with sourcing reliability and cost management.

Comprehensive analysis of how new tariff dynamics will compound supply chain fragility, procurement complexity, and clinical substitution strategies in hospital therapeutics

Tariff policy changes exert a powerful influence across hospital infection therapeutics even when they do not directly affect finished medicines. Increased duties on active pharmaceutical ingredients, sterile componentry, single-use devices, and packaging can raise landed costs and compress margins for manufacturers and distributors. As a consequence, procurement teams face heightened complexity in cost forecasting and contract negotiation, while manufacturers reassess supplier footprints and consider reshoring or nearshoring of critical production stages.

The tariff environment also exacerbates existing supply chain fragilities for parenteral and sterile products, where specialized equipment and validated production sites limit rapid capacity scaling. Hospitals that rely on just-in-time inventory models may experience greater exposure to intermittent shortages, prompting a strategic recalibration toward safety stock, multi-sourcing, and longer contract terms with clause structures that address force majeure and cost pass-through. In parallel, increased import costs can incentivize local manufacturing investment, but such transitions require capital, regulatory relocation, and time, meaning near-term impacts will mainly be managed through contracting strategies and inventory policies.

Clinically, tariff-related shifts can alter the availability and procurement prioritization of certain drug classes. Facilities may prioritize therapeutically equivalent generics or alternative antiseptic formulations to maintain continuity of care. Consequently, antimicrobial stewardship teams must work with procurement and formulary committees to update treatment pathways and ensure substitutions maintain clinical effectiveness while conforming to stewardship goals. Overall, tariff changes act as a forcing function that accelerates coordination across clinical, supply chain, regulatory, and finance functions.

Key Segmentation Insights Across Drug Class, Route of Administration, End User, Distribution Channel, and Application

Understanding the market requires a granular view by drug class, route of administration, end user, distribution channel, and application. The drug class landscape spans antibiotics, antifungals, antiseptics, and antivirals; within antibiotics there are subclasses including carbapenems, cephalosporins, fluoroquinolones, macrolides, and penicillins, while antifungals encompass azoles, echinocandins, and polyenes, antiseptics include alcohol-based preparations, chlorhexidine, and iodophors, and antivirals cover therapies for hepatitis B, hepatitis C, HIV, and influenza. Each of these categories presents distinct clinical usage patterns, stewardship considerations, manufacturing requirements, and regulatory pathways, which together influence procurement priorities and hospital formularies.

Routes of administration are a critical determinant of clinical deployment and supply complexities, with inhalation, oral, parenteral, and topical modalities shaping both clinical pathways and logistics; parenteral delivery in particular breaks down into intramuscular, intravenous, and subcutaneous forms that require specialized sterile manufacturing, cold chain considerations, and nursing competencies for administration. End users such as ambulatory surgery centers, clinics, home healthcare settings, and hospitals differ in purchasing power, storage infrastructure, and treatment protocols, necessitating tailored distribution approaches and patient education strategies. Distribution channels also vary between hospital pharmacy, online pharmacy, retail pharmacy, and wholesalers, each carrying distinct lead times, contractual norms, and compliance obligations.

Application segments-palliative, prophylaxis, and treatment-drive therapeutic selection and inventory planning. Prophylaxis itself subdivides into post-operative and pre-operative use cases that align with scheduling and surgical services, while treatment divides into empirical and targeted therapy, which requires different diagnostic and stewardship support. Integrating these segmentation layers enables stakeholders to better align clinical pathways with supply chain design, ensuring that the right formulation, route, and distribution channel are matched to the appropriate end user and application.

Key Regional Insights and How Geographic Dynamics Shape Clinical Adoption, Manufacturing, and Distribution Strategies

Regional dynamics exert a strong influence on therapeutic availability, regulatory expectations, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among hospital systems and an emphasis on value-based procurement drive demand for therapies that demonstrate clear clinical and economic benefits, while distribution networks are often oriented toward centralized group purchasing and integrated supply agreements. By contrast, Europe, Middle East & Africa present heterogenous regulatory environments and procurement frameworks where national regulations, reimbursement mechanisms, and regional manufacturing hubs shape access and pricing. Policy initiatives stressing antimicrobial stewardship and infection prevention can also vary significantly across jurisdictions.

Asia-Pacific offers diverse dynamics with rapidly expanding healthcare capacity in some markets and advanced manufacturing capabilities in others. Several countries in the region prioritize local production and export-oriented pharmaceutical industries, affecting global supply chains for active pharmaceutical ingredients and sterile components. These geographic differences require manufacturers and distributors to adopt differentiated go-to-market approaches, invest in regulatory intelligence, and develop localized supply chain redundancies. Overall, regional strategy must account for regulatory timelines, procurement customs, manufacturing concentration, and clinical practice variation to ensure both availability and appropriate clinical use.

Key Companies Insights Highlighting Competitive Positioning, Innovation Focus, and Supply Chain Roles

The competitive landscape spans multinational pharmaceutical innovators, specialist biotech companies focused on novel antimicrobials and antivirals, generics manufacturers, and distributors that facilitate hospital access. Industry leaders with broad infectious disease portfolios often combine antiviral and antibacterial R&D with large-scale manufacturing and established distribution networks, enabling rapid deployment of new therapies when clinically validated. Specialist biotech firms and academic spinouts are frequently the source of next-generation agents and adjunctive therapies, while generics and contract manufacturers play a vital role in maintaining cost-effective access and production resilience.

Distribution and pharmacy service providers increasingly differentiate through value-added services such as clinical support tools, stewardship analytics, and managed inventory solutions. This trend has elevated the importance of partnerships between manufacturers and distributors to ensure that stewardship objectives and formulary decisions are supported by timely supply and clinician education. Additionally, companies investing in sterile manufacturing capacity and quality systems are better positioned to serve the hospital parenteral market, where regulatory scrutiny and the need for validated production present high barriers to entry. Insight into these corporate strategies helps stakeholders evaluate partner selection, potential acquisition targets, and collaboration opportunities to strengthen supply continuity and clinical outcomes.

Actionable Recommendations for Industry Leaders to Strengthen Resilience, Stewardship, and Commercial Performance

Industry leaders should prioritize cross-functional governance that brings together clinical, procurement, regulatory, and commercial teams to align on formulary decisions, contract structures, and contingency planning. Strengthening supplier qualification processes and diversifying sources for active pharmaceutical ingredients and sterile components reduces exposure to geographic and policy disruptions. At the same time, investing in diagnostic enablement and stewardship analytics helps shift utilization toward targeted therapy, preserving clinical efficacy and slowing resistance trends.

Commercial and distribution strategies must adapt to evolving procurement behaviors by offering flexible contracting models, accredited supply assurances, and educational support for clinical adoption. Manufacturers with capabilities in sterile manufacturing and robust quality systems should consider capacity signaling and strategic partnerships to support hospital needs. Additionally, building scenario planning into strategic reviews will help organizations respond to tariff changes, regulatory shifts, and sudden demand spikes by clearly defining trigger points for inventory adjustments, alternative sourcing, or therapeutic substitution. Collectively, these steps enhance preparedness while aligning commercial incentives with clinical quality objectives.

Research Methodology Explaining Data Sources, Analytical Frameworks, and Validation Approaches Underpinning Findings

The research approach combined primary engagement with clinical leaders, procurement professionals, and industry executives alongside secondary analysis of regulatory filings, quality guidance, and open-source industry reporting. Qualitative interviews provided context on operational constraints and adoption barriers, while supply chain mapping identified critical nodes for active pharmaceutical ingredient sourcing, sterile componentry, and distribution flows. The analytical framework integrated clinical pathway mapping with supplier risk assessment and commercial channel evaluation to generate holistic insights.

Validation was achieved through triangulation across interview feedback, manufacturer disclosures, and publicly available regulatory action summaries. Scenario analysis was applied to assess resilience under supply disruption and policy shifts, with particular attention to parenteral manufacturing constraints and distribution channel flexibility. Emphasis was placed on transparent assumptions and the reproducibility of method steps so that stakeholders can adapt the approach to their internal decision-making and perform targeted due diligence where necessary.

Conclusion Summarizing Strategic Imperatives for Clinical Outcomes, Supply Continuity, and Collaborative Execution

Hospital infection therapeutics sit at the intersection of clinical urgency and operational complexity. Ensuring patient safety and effective therapeutic access requires integrated action across clinical stewardship, procurement policy, manufacturing strategy, and distribution design. Recent changes in trade policy, evolving clinical diagnostics, and shifting distribution models compound the need for cross-functional coordination and contingency planning. Organizations that proactively diversify supply, invest in diagnostic-driven prescribing, and structure flexible commercial agreements will be better positioned to maintain continuity and support optimal clinical outcomes.

Ultimately, success depends on translating insight into operational practice: aligning formularies with stewardship objectives, qualifying multiple supply sources for critical sterile products, and leveraging partnerships that provide both clinical outreach and inventory solutions. By taking a strategic, integrated approach, hospitals, manufacturers, and distributors can mitigate near-term disruptions and build the adaptive capabilities necessary to respond to future challenges in infection therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of hospital-based antimicrobial stewardship programs reducing resistance emergence by optimizing antibiotic usage
  • 5.2. Adoption of rapid molecular diagnostics enabling targeted infection therapy within hours of patient admission
  • 5.3. Increasing integration of AI-driven predictive analytics for early detection of hospital-acquired infections
  • 5.4. Development of bacteriophage cocktails targeting multidrug-resistant Pseudomonas aeruginosa in critical care settings
  • 5.5. Emergence of monoclonal antibody adjunctive therapies for prevention of Clostridioides difficile infection recurrence
  • 5.6. Implementation of antimicrobial surface coatings on medical devices to prevent biofilm formation in catheters
  • 5.7. Expansion of telehealth-based infectious disease consultation services to manage inpatient antimicrobial protocols
  • 5.8. Regulatory initiatives mandating real-time antibiotic usage tracking and reporting across hospital networks
  • 5.9. Advances in CRISPR-Cas antimicrobials designed to selectively eliminate drug-resistant bacterial strains in hospitals
  • 5.10. Utilization of next-generation sequencing for real-time surveillance of resistance gene transmission pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hospital Infection Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Carbapenems
    • 8.1.2. Cephalosporins
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Penicillins
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antiseptics
    • 8.3.1. Alcohol Based
    • 8.3.2. Chlorhexidine
    • 8.3.3. Iodophors
  • 8.4. Antivirals
    • 8.4.1. Anti-HBV
    • 8.4.2. Anti-HCV
    • 8.4.3. Anti-HIV
    • 8.4.4. Anti-Influenza

9. Hospital Infection Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Oral
  • 9.3. Parenteral
    • 9.3.1. Intramuscular
    • 9.3.2. Intravenous
    • 9.3.3. Subcutaneous
  • 9.4. Topical

10. Hospital Infection Therapeutics Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Clinics
  • 10.3. Home Healthcare
  • 10.4. Hospitals

11. Hospital Infection Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Wholesalers

12. Hospital Infection Therapeutics Market, by Application

  • 12.1. Palliative
  • 12.2. Prophylaxis
    • 12.2.1. Post-Operative
    • 12.2.2. Pre-Operative
  • 12.3. Treatment
    • 12.3.1. Empirical
    • 12.3.2. Targeted Therapy

13. Hospital Infection Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hospital Infection Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hospital Infection Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Sanofi S.A.
    • 16.3.5. F. Hoffmann-La Roche Ltd
    • 16.3.6. Novartis AG
    • 16.3.7. Bayer AG
    • 16.3.8. AbbVie Inc.
    • 16.3.9. Astellas Pharma Inc.
    • 16.3.10. DAIICHI SANKYO COMPANY

LIST OF FIGURES

  • FIGURE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS HOSPITAL